Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Next Previous
Trial Profile

SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tagraxofusp (Primary)
  • Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Stemline Therapeutics

Most Recent Events

  • 25 May 2026 According to a Menarini media release, the data from the trial will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 22 Dec 2025 According to Nippon Shinyaku media release, company has announced that the Ministry of Health, Labour and Welfare (MHLW) has approved ELZONRIS I.V. Injection (Tagraxofusp (genetically recombinant)) for the treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in Japan.
  • 28 Mar 2025 According to a Nippon Shinyaku media release, based on the results of Phase I/II trials conducted overseas in untreated and relapsed/refractory BPDCN patients, tagraxofusp has been approved by European Medicines Agency for adult patients with newly diagnosed BPDCN in January 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top